A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
TherapeuticsMD, Inc. operates in the Pharmaceutical Preparations industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2024 | FY2022 | FY2021 | FY2020 | FY2017 |
|---|---|---|---|---|---|---|
| Revenue | 2.6M | 1.8M | 70M | - | - | - |
| Net Income | -833K | -2.2M | 112M | -172M | -184M | -77M |
| EPS | $-0.06 | $-0.19 | $11.96 | $-21.66 | $-33.50 | $-18.50 |
| Free Cash Flow | 0 | 1.2M | 9.4M | -55M | -160M | -76M |
| ROIC | -17.3% | -8.0% | 78.9% | -22.2% | -108.1% | -59.2% |
| Gross Margin | - | - | 98.0% | - | - | - |
| Debt/Equity | 0.00 | 0.42 | 1.57 | -2.01 | -1.92 | 0.10 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -4.4M | -4.8M | 126M | -80M | -156M | -78M |
| Operating Margin | -169.1% | -270.3% | 179.4% | - | - | - |
| ROE | -3.0% | -7.7% | 318.7% | - | - | -59.8% |
| Shares Outstanding | 12M | 11M | 9M | 8M | 5M | 4M |
| Metric | 2014 | 2015 | 2016 | 2017 | 2020 | 2021 | |||
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | 70M | 1.8M | 2.6M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | 98.0% | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -54M | -85M | -90M | -78M | -156M | -80M | 126M | -4.8M | -4.4M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | 179.4% | -270.3% | -169.1% |
| Net Income | -54M | -85M | -90M | -77M | -184M | -172M | 112M | -2.2M | -833K |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | 160.1% | -123.9% | -31.7% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 9.5M | 1.3M | 1.3M |
| Returns on Capital | |||||||||
| ROIC | -88.2% | -106.7% | -70.5% | -59.2% | -108.1% | -22.2% | 78.9% | -8.0% | -17.3% |
| ROE | -112.0% | -134.9% | -70.5% | -59.8% | N/A | N/A | 318.7% | -7.7% | -3.0% |
| ROA | -91.8% | -115.4% | -63.1% | -53.9% | -101.1% | -101.7% | 86.2% | -5.3% | -2.2% |
| Cash Flow | |||||||||
| Op. Cash Flow | -46M | -79M | -69M | -76M | -159M | -55M | 9.4M | 1.2M | -2.9M |
| Free Cash Flow | -46M | -79M | -70M | -76M | -160M | -55M | 9.4M | 1.2M | 0 |
| Owner Earnings | -51M | -86M | -87M | -83M | -174M | -74M | -3.4M | 397K | -3.7M |
| CapEx | 31K | 165K | 396K | 62K | 207K | 34K | 0 | 0 | 0 |
| Maint. CapEx | 29K | 30K | 78K | 142K | 4.1M | 736K | 1.2M | 509K | 509K |
| Growth CapEx | 2K | 135K | 318K | 0 | 0 | 0 | N/A | N/A | 0 |
| D&A | 29K | 30K | 78K | 142K | 4.1M | 736K | 1.2M | 509K | 509K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 5.0M | 7.2M | 17M | 6.9M | 11M | 18M | 12M | 264K | 264K |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 50M | 219M | 0 | 0 |
| Balance Sheet | |||||||||
| Net Debt | N/A | N/A | N/A | N/A | 238M | 377M | N/A | N/A | -7.1M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 7.1M |
| Long-Term Debt | N/A | N/A | N/A | N/A | 238M | 188M | N/A | N/A | N/A |
| Debt/Equity | 0.22 | 0.17 | 0.12 | 0.10 | -1.92 | -2.01 | 1.57 | 0.42 | 0.00 |
| Interest Coverage | -207.8 | N/A | N/A | N/A | -5.4 | -3.2 | 9.3 | N/A | N/A |
| Equity | 48M | 63M | 127M | 130M | -124M | -94M | 35M | 27M | 27M |
| Total Assets | 59M | 74M | 142M | 143M | 182M | 169M | 90M | 39M | 39M |
| Total Liabilities | 11M | 11M | 15M | 13M | 306M | 263M | 55M | 11M | 2.0M |
| Intangibles | 2.5M | 3.2M | 4.8M | 6.2M | 83M | 14M | 14M | 8.6M | 8.6M |
| Retained Earnings | -135M | -220M | -310M | -387M | -879M | -1.1B | -939M | -952M | -952M |
| Working Capital | 46M | 60M | 124M | 126M | 69M | -133M | 8.5M | 7.1M | 7.1M |
| Current Assets | 56M | 71M | 139M | 140M | 128M | 119M | 55M | 12M | 12M |
| Current Liabilities | 11M | 11M | 15M | 13M | 59M | 253M | 47M | 5.2M | 5.2M |
| Per Share Data | |||||||||
| EPS | -18.00 | -24.50 | -23.00 | -18.50 | -33.50 | -21.66 | 11.96 | -0.19 | -0.06 |
| Owner EPS | -16.77 | -24.84 | -22.17 | -20.01 | -31.80 | -9.30 | -0.36 | 0.03 | -0.32 |
| Book Value | 16.07 | 18.16 | 32.63 | 31.24 | -22.63 | -11.76 | 3.75 | 2.38 | 2.37 |
| Cash Flow/Share | -15.11 | -22.76 | -17.69 | -18.31 | -29.11 | -6.93 | 1.00 | 0.10 | -0.03 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 3.0M | 3.5M | 3.9M | 4.2M | 5.5M | 8.0M | 9.4M | 11.5M | 11.6M |
| Valuation | |||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | 0.5 | N/A | -35.2 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | 5.7 | 10.7 | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 13.2 | 30.0 | 9.2 | 9.5 | N/A | N/A | 1.5 | 0.5 | 0.9 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | 1.3 | 12.2 | 9.3 |
| FCF Yield | -7.2% | -4.2% | -6.0% | -6.2% | -47.8% | -34.7% | 17.7% | 9.4% | N/A |
| Market Cap | 637M | 1.9B | 1.2B | 1.2B | 334M | 159M | 53M | 13M | 24M |
| Avg. Price | 249.56 | 327.50 | 360.13 | 281.80 | 76.77 | 53.50 | 9.96 | 1.87 | 2.11 |
| Year-End Price | 211.50 | 544.50 | 299.00 | 296.50 | 61.00 | 20.00 | 5.65 | 1.09 | 2.11 |
TherapeuticsMD, Inc. passes 2 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 20.7x vs a median of 8.2x. The company's 5-year average gross margin is 98.0%. At current prices, the estimated annualized return to fair value is -37.0%.
TherapeuticsMD, Inc. (TXMD) has a 5-year average return on invested capital (ROIC) of -23.7%. This is below average and may indicate limited pricing power.
TherapeuticsMD, Inc. (TXMD) has a market capitalization of $24M. It is classified as a small-cap stock.
TherapeuticsMD, Inc. (TXMD) does not currently pay a regular dividend.
TherapeuticsMD, Inc. (TXMD) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
TherapeuticsMD, Inc. (TXMD) reported annual revenue of $2 million in its most recent fiscal year, based on SEC EDGAR filings.
TherapeuticsMD, Inc. (TXMD) has a net profit margin of -123.9%. The company is currently unprofitable.
TherapeuticsMD, Inc. (TXMD) generated $1 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
TherapeuticsMD, Inc. (TXMD) has a debt-to-equity ratio of 0.42. This indicates a conservatively financed balance sheet.
TherapeuticsMD, Inc. (TXMD) reported earnings per share (EPS) of $-0.19 in its most recent fiscal year.
TherapeuticsMD, Inc. (TXMD) has a return on equity (ROE) of -7.7%. A negative ROE may indicate losses or negative equity.
TherapeuticsMD, Inc. (TXMD) has a 5-year average gross margin of 98.0%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 8 years of financial data for TherapeuticsMD, Inc. (TXMD), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
TherapeuticsMD, Inc. (TXMD) has a book value per share of $2.38, based on its most recent annual SEC filing.